Silo Pharma, Inc.

Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility

Silo Pharma's wholly owned AI subsidiary QwikAgents added support for customer-supplied NVIDIA API keys and NVIDIA's Nemotron models, now live on the platform. NVIDIA is the fifth bring-your-own-key provider alongside Anthropic, OpenAI, Google and DeepSeek, and QwikAgents added Hermes as a second agent runtime option alongside OpenClaw. The update strengthens platform flexibility at the AI unit, but Silo remains a developmental-stage biopharma with no revenue impact disclosed in this release.

•1mo ago

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

Silo Pharma received a Notice of Allowance from the USPTO for a patent application covering SPC-15, its lead intranasal therapeutic candidate targeting post-traumatic stress disorder. The allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses, and a corresponding patent was already issued by the Japan Patent Office earlier this year. CEO Eric Weisblum called U.S. patent protection an important component of the SPC-15 strategy as the drug advances in development; with examination complete, formal grant is expected shortly. Silo remains a developmental-stage biopharma with SPC-15 (PTSD), SP-26 (fibromyalgia and chronic pain), and a preclinical Alzheimer's asset, alongside its wholly owned AI subsidiary QwikAgents.

•1mo ago

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

Silo Pharma will participate in the IPAC-RS 2026 Nasal Innovation Forum on September 16-17, 2026, in Jersey City, New Jersey. CEO Eric Weisblum framed the forum as an opportunity to engage nasal drug development experts as the company advances SPC-15, its nose-to-brain targeted delivery program for PTSD. Preclinical data showed SPC-15's formulation and device met specifications for assay, impurities, pH, and microbiological quality over a nine-month period, with six-month accelerated stability data consistent with long-term results. Silo's pipeline also includes SP-26 for fibromyalgia and chronic pain and a preclinical Alzheimer's asset, alongside its wholly owned QwikAgents AI agent platform subsidiary.

•2mo ago

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Silo Pharma announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal 5-HT4 receptor agonist targeting PTSD. This allowance strengthens the company's global IP position, adding to a recently granted European patent and falling under an exclusive license agreement with Columbia University. The company intends to utilize the FDA's 505(b)(2) regulatory pathway for SPC-15, aiming to shorten clinical timelines and reduce development costs.

•2mo ago

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Silo Pharma announced that the European Patent Office has granted a patent covering the preventative approach of its lead candidate SPC-15 for PTSD and stress-induced affective disorders. The patent protects methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists administered prior to trauma exposure. This milestone strengthens the global IP position for SPC-15 and complements existing protection in five other major markets under an exclusive license from Columbia University.

•2mo ago

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

Silo Pharma's subsidiary QwikAgents has engaged Caylent, an AWS Premier Tier Services Partner, to design and build a new AWS-native platform. The collaboration aims to preserve core functionality while enhancing scalability, performance, and security for enterprise deployment and future innovation. The engagement is structured to align with AWS funding programs, with financial support expected from both AWS and Caylent.

•3mo ago

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Silo Pharma expects to commercially launch its AI subsidiary QwikAgents within the next 60 days, targeting initial revenue from the enterprise workflow automation platform. The company continues advancing its lead PTSD therapeutic candidate SPC-15, with a robustness study on its nasal spray delivery system expected to complete in about 60 days ahead of a planned FDA Type C meeting. Management cites recent capital raises as sufficient to support both the AI commercialization and the preclinical pipeline into the second half of 2026.

•3mo ago

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Silo Pharma announced its wholly owned subsidiary, QwikAgents, has been accepted into the AMD AI Developer Program. The program provides access to AMD Developer Cloud credits, AI tools, and technical resources to support the acceleration of QwikAgents' enterprise AI platform development. QwikAgents is building a platform for persistent AI agents with starter plans beginning at $14 per month, targeting use cases in research, content generation, and workflow automation.

•3mo ago

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

Silo Pharma engaged partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system for its lead asset SPC-15. The study assesses device performance consistency and formulation stability over a 30-day period, intended to support a planned FDA Type C meeting request. Management intends to use the data to obtain regulatory guidance on the IND strategy and Phase 1 clinical trial design for the PTSD prophylactic treatment.

•4mo ago

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

Silo Pharma confirmed positive nine-month stability data for its investigational PTSD treatment SPC-15, supporting the advancement of its IND-enabling development program. The data demonstrated that the formulation maintains integrity under long-term and accelerated storage conditions, validating adherence to cGMP standards required for regulatory submission. SPC-15 is a preclinical intranasal serotonin agonist targeting stress-induced psychiatric disorders, with plans to advance into a first-in-human Phase 1 study.

•4mo ago

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Silo Pharma received confirmation from Nasdaq that it has regained compliance with the minimum closing bid price requirement as of June 17, 2026, closing the matter on its listing status. CEO Eric Weisblum expressed gratitude for investor support and confirmed the company remains on track to advance its lead drug SPC-15 toward a first-in-human clinical trial for PTSD. The company continues to focus on developing therapeutics for stress-induced psychiatric disorders and central nervous system diseases.

•4mo ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Silo Pharma filed a provisional patent application for ibogaine-based therapeutics targeting traumatic brain injury (TBI) and associated neuropsychiatric conditions. The initiative aligns with a recent federal Executive Order to accelerate psychedelic medicine innovation, targeting a market estimated to reach $6 billion by 2032. CEO Eric Weisblum noted that no current FDA-approved therapies address the structural aspects of TBI, positioning this approach as a potential paradigm shift in neurotherapeutics.

•6mo ago

Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Silo Pharma is commending a wave of federal initiatives and FDA actions designed to accelerate the development of psychedelic-based therapeutics for mental health disorders. The FDA granted priority vouchers to peer companies and confirmed that final guidance for psychedelic drug development will be published imminently. Silo's portfolio includes SPC-15 for PTSD and SP-26 for fibromyalgia, positioning the company to potentially benefit from these sector-wide regulatory tailwinds.

•6mo ago

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Silo Pharma acquired the assets of Qwikagents.ai to launch a dedicated AI subsidiary, marking a strategic diversification beyond its biopharma roots into the autonomous agent market. The new business unit targets a sector projected to reach $47–$53 billion by 2030, with proprietary smart-routing technology aimed at optimizing cost and performance. Management emphasized that the expansion will not disrupt its core operations, confirming that the PTSD program SPC-15 remains on track for Phase 1 clinical trials.

•6mo ago